Novo Nordisk Announces Global Transformation to Enhance Agility and Drive Growth

Strategic Insights -

As the global leader in obesity and diabetes, Novo Nordisk is undergoing a company-wide transformation to simplify its organization, improve decision-making speed, and reallocate resources towards growth opportunities in diabetes and obesity. Part of this transformation involves reducing the global workforce by approximately 9,000 positions, with around 5,000 reductions expected in Denmark. This move aims to address the complexity resulting from rapid scaling, enabling the company to invest more in science, commercial capabilities, and manufacturing ramp-up, ultimately reaching the millions of people who remain untreated.

Key Takeaways:

  • Novo Nordisk plans to reduce approximately 9,000 roles globally to achieve DKK 8bn of annualised savings by the end of 2026.
  • The workforce reduction is expected across the company, including staff areas and headquarters functions, and is expected to deliver total annualised savings of around DKK 8 billion by the end of 2026.
  • The savings will be redirected to growth opportunities in diabetes and obesity, including commercial execution initiatives and R&D programmes.
  • Novo Nordisk expects to incur one-off restructuring costs of around DKK 8 billion, including impairment charges, which will have an estimated impact of 6 percentage points on full-year operating profit growth at CER in 2025 compared to the operating profit outlook issued on August 6.
  • The company's transformation plan includes initiatives to enhance organisational focus, performance culture, and speed of decision-making as well as cost efficiencies.
  • Novo Nordisk's purpose is to drive change to defeat serious chronic diseases built upon its heritage in diabetes, and the transformation aims to help the company achieve this goal by becoming faster and more agile.

Statistics:

  • Novo Nordisk plans to reduce approximately 9,000 roles globally (around 11.3% of its total workforce of 79,400).
  • The workforce reduction is expected in staff areas and headquarters functions, with around 5,000 reductions expected in Denmark.
  • Novo Nordisk expects to incur one-off restructuring costs of around DKK 8 billion, including impairment charges.
  • The transformation is expected to deliver total annualised savings of around DKK 8 billion by the end of 2026.
  • The company's initial restructuring costs will be incurred in the third quarter of 2025, countered by savings of around DKK 1 billion in the fourth quarter of the same year.

Sources:

  • "Novo Nordisk issues statement on company-wide transformation." Novo Nordisk, September 10, 2025.
  • Company Announcement No 20/2025, Financial report for the first six months of 2025, page 26.
  • Novo Nordisk's disclosure of the financial results for the first nine months of 2025 and financial outlook for 2025 will be published on November 5, 2025.